CBFA2T3 (MTG16), CBFA2/RUNX1 Partner Transcriptional Co-Repressor 3, has not been clearly studied in lung cancer (Zhang et al., 2018) although the CBFA2T3-GLIS2 fusion transcript is well proven as a novel common feature in pediatric cytogenetically normal acute myeloid leukemia (AML) (Gruber et al., 2012; Masetti et al., 2013; Smith et al., 2020). Here, RUNX1 is linked to lung carcinoma.